<DOC>
	<DOCNO>NCT00085904</DOCNO>
	<brief_summary>SB-485232 administer five daily intravenous ( IV ) infusion repeat every 28 day adult subject advance solid tumor lymphomas . Subjects may receive 6 cycle treatment unless progressive disease unacceptable toxicity note . Three dose level drug investigate . Safety evaluation , include blood sample various laboratory test , conduct . Additional blood sample also take measure amount drug body specific time .</brief_summary>
	<brief_title>Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Inclusion criterion : Histopathological confirmation cancer limit solid tumor malignancy follicular lymphoma . Advanced metastatic disease . Measurable disease . Females childbearing potential must use adequate birth control . Karnofsky Performance Status 70 % great . Predicted life expectancy least 12 week estimation physician conduct study ( Principal Investigator ) . Adequate laboratory result . Subjects history coronary artery disease must stress test without clinically significant abnormality . Subjects history congestive heart failure , myocardial infarction prior anthracycline chemotherapy , must MUGA ( Multiple Gated Acquisition ) scan demonstrate leave ventricular ejection fraction equal great 40 % . Signed informed consent form Female subject pregnant nursing ( lactate ) . Active , chronic uncontrolled infection require systemic antibiotic therapy . Serious medical psychiatric disorder would interfere subject '' safety ability sign inform consent . Leptomeningeal disease evidence prior current metastatic brain disease . Receiving concurrent chemotherapy , immunotherapy , radiotherapy , corticosteroid therapy , investigational therapy . Received chemotherapy , radiotherapy , immunotherapy , hormonal therapy biological therapy cancer underwent surgical procedure ( except minor surgical procedure ) within 4 week begin treatment SB485232 ( 6 week case nitrosureas mitomycin C ) . Exposed investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose SB485232 . Severe concurrent disease condition , include clinically significant autoimmune disease , judgement physician conduct study ( principal investigator ) would render patient inappropriate study participation . History ventricular arrhythmia require drug device therapy . An unresolved unstable , serious toxicity prior administration another investigational product . Psychological , familial , sociological , geographical limitation permit compliance protocol . Received prior SB485232 therapy . Poor venous access .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Advanced cancer</keyword>
	<keyword>IL-18</keyword>
	<keyword>repeat dose</keyword>
	<keyword>Phase 1</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>oncology</keyword>
</DOC>